Autres langues Dechra Pharmaceuticals

Actions

DPH

GB0009633180

Marché Fermé - London S.E. 08:30:00 16/01/2024			Varia. 5j.	Varia. 1 janv.
3 866,00 ^GBX	-.--%		-.--%	-

17/08	Dechra Pharmaceuticals PLC annonce la nomination de Justine Conway au poste de directrice de la stratégie d'entreprise et du développement commercial	CI
25/06	Dechra inaugure son nouveau siège mondial à Boston et investit 60 000 dollars dans des partenariats locaux	CI

Autres langues

17/08	Dechra Pharmaceuticals PLC Announces Appointment of Justine Conway as Chief Corporate Strategy and Business Development Officer
25/06	Dechra Opens New Global Headquarters in Boston and Invests $60,000 in Local Community Partnerships
19/05	Dechra Veterinary Products LLC Announces FDA Approval Of Cosacthen Cosyntropin Injection For Canine Patients
31/03	Dechra Pharmaceuticals Limited Announces Termination of Jonathan David Lang as Director, Effective March 31, 2026
11/03	Dechra Announces Consolidation Of Its Existing U.S. Office Footprint In Kansas City, Kan. And Portland, Maine
11/03	Dechra Announces Plans to Relocate Its Global Headquarters from Northwich, England, to Boston, Massachusetts
13/10/25	Intervacc Extends Equine Strangles Vaccine Distribution Deal with Dechra Pharmaceuticals
13/10/25	Intervacc and Dechra Extend Distribution Agreement for Intervacc's Equine Strangle Vaccine Strangvac by Two Years
03/09/25	Dechra Pharmaceuticals Limited completed the acquisition of Invetx, Inc. from a group of shareholders for approximately $530 million
18/08/25	Dechra Pharmaceuticals PLC Launches Strangvac in Spain, Portugal and Slovenia
17/06/25	Vaxxinova GmbH acquired Poultry Vaccines Business of Dechra Pharmaceuticals Limited.
05/05/25	Dechra Pharmaceuticals to Launch Intervacc's Horse Vaccine in Finland
05/05/25	Dechra Pharmaceuticals plc Launches Strangvac in Finland
18/07/24	Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million.
10/06/24	Dechra Pharmaceuticals Limited Appoints Jonathan David Lang as Director
15/04/24	Dechra Pharmaceuticals Limited acquired 33.34% stake in STEM Animal Health Inc.
11/04/24	Dechra Pharmaceuticals Limited reached agreement in principle to acquire 33.34% stake in STEM Animal Health Inc. for $4.7 million.
09/04/24	Dechra Group Holdings Limited Appoints Paul Nicholas Sandland as Director
09/04/24	Dechra Group Holdings Limited Appoints Ian David Page as Director
09/04/24	Dechra Group Holdings Limited Announces Resignation of Thomas Spicer as Director
09/04/24	Dechra Group Holdings Limited Announces Resignation of Anthony Santospirito as Director
09/04/24	Dechra Group Holdings Limited Announces Resignation of Sara Huda as Director
17/01/24	Stocks slump as Fed rate cut hope dwindles
17/01/24	Dechra Pharmaceuticals Delists From London Bourse Following Freya Bidco’s Takeover
16/01/24	EQT's Freya Bidco Completes Dechra Pharmaceuticals Purchase